📊 ENVB Key Takeaways
Is Enveric Biosciences, Inc. (ENVB) a Good Investment?
Enveric Biosciences is in severe financial distress with collapsing revenues (-94.1% YoY), persistent operating losses, and negative free cash flow of -6.4M, indicating the company is burning through its limited cash reserves. Despite adequate near-term liquidity (4.6x current ratio), the company is losing money at an alarming rate with -$6.6M net loss in the latest period, and without meaningful revenue growth or a clear path to profitability, the business model appears fundamentally broken.
Enveric Biosciences shows extremely weak fundamentals: revenue is effectively nonexistent, operating losses remain large relative to its asset base, and free cash flow is deeply negative. While the balance sheet currently shows solid near-term liquidity, the company’s cash burn and lack of durable commercial revenue make the business fundamentally fragile without external financing or a major operating turnaround.
Why Buy Enveric Biosciences, Inc. Stock? ENVB Key Strengths
- Strong current ratio of 4.60x provides short-term liquidity buffer
- Moderate debt burden with Debt/Equity ratio of 0.21x
- Maintains $3.8M in cash and equivalents for operational continuity
- Cash of $3.76M supports near-term operations better than many micro-cap biotech peers
- Current and quick ratios of 4.60x indicate limited immediate liquidity stress
- Debt load is modest relative to equity, with debt/equity of 0.21x
ENVB Stock Risks: Enveric Biosciences, Inc. Investment Risks
- Revenue collapsed 94.1% YoY indicating severe business deterioration
- Operating losses of -$6.6M with negative operating margin of -4,569,809%
- Negative free cash flow of -$6.4M will deplete cash reserves within months if trend continues
- Company is unprofitable with no clear evidence of path to profitability
- Pharmaceutical sector requires sustained R&D investment; current cash burn is unsustainable
- Revenue collapsed 94.1% YoY to just $144, indicating no meaningful operating scale or revenue stability
- Operating loss of $6.58M and negative free cash flow of $6.36M imply continued heavy cash consumption
- Very small asset base and negative returns on equity/assets suggest weak financial resilience if funding conditions tighten
Key Metrics to Watch
- Quarterly revenue trends and any stabilization signals
- Cash runway and timeline to potential insolvency
- Operating cash burn rate and path to profitability
- Clinical trial progress or regulatory milestones that could revive revenue
- Management changes or strategic pivots that indicate course correction
- Quarterly operating cash burn relative to cash balance
- Any sustained revenue generation or commercialization progress
Enveric Biosciences, Inc. (ENVB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.60x current ratio provides a solid financial cushion.
ENVB Profit Margin, ROE & Profitability Analysis
ENVB vs Healthcare Sector: How Enveric Biosciences, Inc. Compares
How Enveric Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enveric Biosciences, Inc. Stock Overvalued? ENVB Valuation Analysis 2026
Based on fundamental analysis, Enveric Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enveric Biosciences, Inc. Balance Sheet: ENVB Debt, Cash & Liquidity
ENVB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Enveric Biosciences, Inc.'s revenue has declined by 12% over the 5-year period, indicating business contraction. The most recent EPS of $-228.48 indicates the company is currently unprofitable.
ENVB Revenue Growth, EPS Growth & YoY Performance
ENVB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $8.5M | $41.3K | $-0.03 |
| Q2 2020 | $8.3M | -$1.3M | $-0.48 |
| Q1 2020 | $9.6M | -$1.8M | $-0.60 |
| Q3 2019 | $9.1M | $41.3K | $0.00 |
| Q2 2019 | $11.0M | -$1.3M | $-0.03 |
| Q1 2019 | $10.7M | -$1.6M | $-0.04 |
| Q3 2018 | $10.6M | $388.7K | $0.02 |
| Q2 2018 | $11.1M | -$1.3M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Enveric Biosciences, Inc. Dividends, Buybacks & Capital Allocation
ENVB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enveric Biosciences, Inc. (CIK: 0000890821)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENVB
What is the AI rating for ENVB?
Enveric Biosciences, Inc. (ENVB) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENVB's key strengths?
Claude: Strong current ratio of 4.60x provides short-term liquidity buffer. Moderate debt burden with Debt/Equity ratio of 0.21x. ChatGPT: Cash of $3.76M supports near-term operations better than many micro-cap biotech peers. Current and quick ratios of 4.60x indicate limited immediate liquidity stress.
What are the risks of investing in ENVB?
Claude: Revenue collapsed 94.1% YoY indicating severe business deterioration. Operating losses of -$6.6M with negative operating margin of -4,569,809%. ChatGPT: Revenue collapsed 94.1% YoY to just $144, indicating no meaningful operating scale or revenue stability. Operating loss of $6.58M and negative free cash flow of $6.36M imply continued heavy cash consumption.
What is ENVB's revenue and growth?
Enveric Biosciences, Inc. reported revenue of $144.0.
Does ENVB pay dividends?
Enveric Biosciences, Inc. does not currently pay dividends.
Where can I find ENVB SEC filings?
Official SEC filings for Enveric Biosciences, Inc. (CIK: 0000890821) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENVB's EPS?
Enveric Biosciences, Inc. has a diluted EPS of $-35.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENVB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Enveric Biosciences, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENVB stock overvalued or undervalued?
Valuation metrics for ENVB: ROE of -190.3% (sector avg: 15%), net margin of -4,567,927.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENVB stock in 2026?
Our dual AI analysis gives Enveric Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENVB's free cash flow?
Enveric Biosciences, Inc.'s operating cash flow is $-6.4M, with capital expenditures of $5.2K. FCF margin is -4,417,958.3%.
How does ENVB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,567,927.8% (avg: 12%), ROE -190.3% (avg: 15%), current ratio 4.60 (avg: 2).